October 25, 2017
A recent Mayo Clinic study has found that many U.S. health care providers are habitually ordering a mostly unnecessary and quite expensive genetic test to identify a patient’s hereditary risk of venous thromboembolism.
February 16, 2017
Drugs targeting the P13K-mTOR pathway add benefit when combined with standard R-CHOP therapy. The drug everolimus can be safely combined with R-CHOP for new, untreated diffuse large B-cell lymphoma, according to the results of a pilot study by Mayo Clinic researchers. The researchers published their study findings in the July 2016 issue of […]